Browsing by Author "Orman S."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    The effect of steam sterilization on antioxidant activities of Sage, Oregano and Basil
    (Codon Publications, 2010) Lioglu N.B.; Orman S.
    Sage, oregano and basil are aromatic herbs showing strong antioxidant activity. Total phenolic contents (279.1, 258.3 and 84.4 mg GAE/g), DPPH* radical-scavenging activity (EC50 values 2.07, 2.64 and 9.26), metal chelating activities (82.6, 63.9 and 92.9%) and hydrogen peroxide scavenging capacity (89.7, 97.2 and 7.4%) were determined for sage, oregano and basil, respectively. Total phenolic content and antioxidant activity of sage samples were not significantly influenced by the steam sterilization process, but basil was. Steam sterilization significantly reduced the total phenolic content, and hydrogen peroxide scavenging capacity of oregano. © 2010.
  • No Thumbnail Available
    Item
    The effect of irradiation on antioxidant activities of sage, oregano and basil
    (2013) Bagdatlioglu N.; Taskin B.; Orman S.
    [No abstract available]
  • No Thumbnail Available
    Item
    Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
    (Multidisciplinary Digital Publishing Institute (MDPI), 2025) Sever N.; Şimşek F.; Onur İ.D.; Arvas H.; Guliyev T.; Şakalar T.; Çiçek C.M.; Orman S.; Çetin E.B.; Kayaş K.; Akbaş S.; Ağyol Y.; Güren A.K.; Erel P.; Kocaaslan E.; Paçacı B.; Tunç M.A.; Çelebi A.; Majidova N.; Durnalı A.; Şimşek M.; Şahbazlar M.; Işık S.; Arıkan R.; Ercelep Ö.; Sarı M.; Köstek O.; Bayoğu İ.V.
    Background: Osteosarcoma is a rare but aggressive bone malignancy. Despite advances in multimodal therapy, survival remains suboptimal, highlighting the need for prognostic markers to guide treatment. Methods: This study included 162 osteosarcoma patients who received neoadjuvant chemotherapy followed by surgery between January 2009 and March 2024. Patients received either double (cisplatin + doxorubicin) or triple (MAP or PEI) chemotherapy. Survival analyses were conducted using Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models. Results: The median age was 20 years (IQR: 18–29), and 53.1% were male. Patients who received triple chemotherapy regimens demonstrated significantly longer overall survival (OS) compared to those on doublet regimens. High tumor necrosis rates (>90%) and negative surgical margins were strongly associated with improved OS, while metastatic disease at diagnosis, elevated alkaline phosphatase (ALP), and male gender were linked to poorer survival. Multivariate analysis identified adjuvant therapy, age under 18, high necrosis rate, negative margins, and normal ALP as significant OS predictors. Conclusions: Triple-agent chemotherapy, necrosis rate ≥90 and negative surgical margins are strongly associated with prolonged survival in osteosarcoma. The key prognostic indicators such as ALP levels, surgical margins and age at diagnosis should guide personalized treatment strategies to improve outcomes in curable patients. © 2025 by the authors.
  • No Thumbnail Available
    Item
    Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
    (Multidisciplinary Digital Publishing Institute (MDPI), 2025) Tünbekici S.; Yuksel H.C.; Acar C.; Sahin G.; Orman S.; Majidova N.; Coskun A.; Seyyar M.; Dilek M.S.; Kara M.; Dıslı A.K.; Demir T.; Kolkıran N.; Sahbazlar M.; Demırcıler E.; Kuş F.; Aytac A.; Menekse S.; Yucel H.; Biter S.; Koseci T.; Unsal A.; Ozveren A.; Sevınc A.; Goker E.; Gürsoy P.
    Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies. © 2024 by the authors.